Figure 5.

Longer VSV lags have a detrimental effect on therapeutic success. (A) Inspired by the results for enhancer multiplicity, the effects of the length of VSV lags were investigated by simulating either a single enhancer protocol (left) or a seven enhancer protocol (right). VSV lags were varied from 1 to 15 days after the final enhancer. Tumor growth was assessed 15 days after the administration of the last VSV. (B) Distribution in number of tumor cells 15 days after VSV administration with respect to the duration of VSV lag after 1 (orange) or 7 (blue) enhancers. Central mark (red) indicates median, bottom edge denotes the bottom quartile, top edge denotes the top quartile and individual virtual patient values are plotted as circles. (C) Tumor growth as a function of time. Markers indicate significant differences in final tumor size (t-test, $\mathrm{p}\S amp;gt;0.05$). (D) Cytokine concentrations as a function of time. (E) Immune cells as a function of time. In C, D, E: 1 enhancer, 1-day VSV lag (solid blue), 7 enhancers, 1-day VSV lag (dashed blue), 1 enhancer, 15-day VSV lag (solid red), 7 enhancers, 15-day VSV lag (dashed red). VSV: vesicular stomatitis virus; VV: vaccinia virus.